Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma.

MedStar author(s):
Citation: Expert Review of Hematology. 11(10):773-780, 2018 10.PMID: 30139285Institution: MedStar Washington Hospital CenterDepartment: Hematology and OncologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | *Hodgkin Disease/dt [Drug Therapy] | Bleomycin/tu [Therapeutic Use] | Dacarbazine/tu [Therapeutic Use] | Doxorubicin/tu [Therapeutic Use] | Female | Hodgkin Disease/ep [Epidemiology] | Humans | Immunoconjugates/tu [Therapeutic Use] | Male | Recurrence | United States/ep [Epidemiology] | Vinblastine/tu [Therapeutic Use]Year: 2018ISSN:
  • 1747-4094
Name of journal: Expert review of hematologyAbstract: INTRODUCTION: Hodgkin lymphoma (HL) accounts for about 10% of all lymphomas in the United States. Exceptional progress has been made in the treatment of HL with complete response rates up to 94% in limited stage and 88% in advanced stage disease with regimens such as adriamycin, bleomycin, vinblastine, dacarbazine in the frontline setting. Nevertheless, up to 10% of patients with limited stage disease and 20-30% of those with advanced stage HL relapse. In the last decade, newer agents such as brentuximab vedotin (BV) and checkpoint inhibitors have been approved by the FDA for treatment of patients with relapsed or refractory HL. As these newer agents are increasingly incorporated in both the front-line and relapsed settings, their optimal sequence becomes challenging for clinicians. Areas covered: This review will discuss the evidence behind the approval of BV and checkpoint inhibitors in HL and the appropriate sequence for using them in relapsed Hodgkin lymphoma. Expert Commentary: The appropriate sequence of BV and/or checkpoint inhibitors in the relapsed setting depends on the regimen used in the frontline setting.All authors: Cheson B, Narkhede M, Sarraf Yazdy MFiscal year: FY2019Digital Object Identifier: Date added to catalog: 2018-08-31
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30139285 Available 30139285

INTRODUCTION: Hodgkin lymphoma (HL) accounts for about 10% of all lymphomas in the United States. Exceptional progress has been made in the treatment of HL with complete response rates up to 94% in limited stage and 88% in advanced stage disease with regimens such as adriamycin, bleomycin, vinblastine, dacarbazine in the frontline setting. Nevertheless, up to 10% of patients with limited stage disease and 20-30% of those with advanced stage HL relapse. In the last decade, newer agents such as brentuximab vedotin (BV) and checkpoint inhibitors have been approved by the FDA for treatment of patients with relapsed or refractory HL. As these newer agents are increasingly incorporated in both the front-line and relapsed settings, their optimal sequence becomes challenging for clinicians. Areas covered: This review will discuss the evidence behind the approval of BV and checkpoint inhibitors in HL and the appropriate sequence for using them in relapsed Hodgkin lymphoma. Expert Commentary: The appropriate sequence of BV and/or checkpoint inhibitors in the relapsed setting depends on the regimen used in the frontline setting.

English

Powered by Koha